Variants in , and Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2021 Apr 1

PMID 33790638

Citations 3

Authors

Mansour A Alghamdi

Laith Al-Eitan

Rami Alkhatib

Ahmad Al-Assi

Ayah Almasri

Hanan Aljamal

Hatem Aman

Rame Khasawneh

Affiliations

Soon will be listed here.

Abstract

Introduction: Warfarin has been in use for more than 60 years; however, it has serious side effects including major bleeding. The high interpatient variability in the required dose impacts the sensitivity and responsiveness to warfarin in different patients. This study aims to assess the influence of , and gene polymorphisms on the variability of warfarin dose requirements and susceptibility to coronary heart disease in the Jordanian population.

Methods: This study was conducted in the anti-coagulation clinic in Queen Alia Heart Institute in Amman, with 212 patients in total. Three SNPs were genotyped within (rs10270308), (rs216013), and (rs1041981) genes.

Results: Our findings revealed that patients with LTA polymorphism are more prone to warfarin sensitivity than others. Furthermore, carriers of the LTA polymorphism needed a lower initial dose of warfarin and are associated with less variation in doses required to achieve target INR.

Conclusion: The current study could help in understanding the role of genetic variability in warfarin dosing and matching patients to different treatment options. Clinical applications of these findings for warfarin treatment may also contribute to improving the efficacy and safety of warfarin treatment in Jordanian patients with cardiovascular disease.

Citing Articles

PTPRD gene variant rs10739150: A potential game-changer in hypertension diagnosis.

Al-Eitan L PLoS One. 2024; 19(6):e0304950.

PMID: 38935682 PMC: 11210811. DOI: 10.1371/journal.pone.0304950.

ACE gene polymorphism and susceptibility to hypertension in a Jordanian adult population.

Al-Eitan L, Al-Khaldi S, Ibdah R PLoS One. 2024; 19(6):e0304271.

PMID: 38917192 PMC: 11198757. DOI: 10.1371/journal.pone.0304271.

Effect of MEF2A and SLC22A3-LPAL2-LPA gene polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients.

Al-Eitan L, Almasri A, Alnaamneh A, Mihyar A PLoS One. 2023; 18(11):e0294226.

PMID: 37948393 PMC: 10637663. DOI: 10.1371/journal.pone.0294226.

References

Tavares L, Marcatto L, Santos P . Genotype-guided warfarin therapy: current status. Pharmacogenomics. 2018; 19(7):667-685. DOI: 10.2217/pgs-2017-0207. View

Mak M, Lam C, Pineda S, Lou M, Xu L, Meeks C . Pharmacogenetics of Warfarin in a Diverse Patient Population. J Cardiovasc Pharmacol Ther. 2019; 24(6):521-533. DOI: 10.1177/1074248419843530. View

Pouladi N, Bime C, Garcia J, Lussier Y . Complex genetics of pulmonary diseases: lessons from genome-wide association studies and next-generation sequencing. Transl Res. 2015; 168:22-39. PMC: 4658294. DOI: 10.1016/j.trsl.2015.04.016. View

Fawzy A, Lip G . Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019; 15(5):381-398. DOI: 10.1080/17425255.2019.1604686. View

Eriksson N, Wallentin L, Berglund L, Axelsson T, Connolly S, Eikelboom J . Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016; 17(13):1425-39. DOI: 10.2217/pgs-2016-0061. View

Kampouraki E, Kamali F . Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019; 15(6):449-458. DOI: 10.1080/17425255.2019.1623878. View

Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, Parish S . Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet. 2006; 2(7):e107. PMC: 1487176. DOI: 10.1371/journal.pgen.0020107. View

Al-Eitan L, Almasri A, Al-Habahbeh S . Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy. Pharmgenomics Pers Med. 2019; 12:1-8. PMC: 6338106. DOI: 10.2147/PGPM.S189458. View

Gamazon E, Konkashbaev A, Derks E, Cox N, Lee Y . Evidence of selection on splicing-associated loci in human populations and relevance to disease loci mapping. Sci Rep. 2017; 7(1):5980. PMC: 5519721. DOI: 10.1038/s41598-017-05744-9. View

10.

Beitelshees A, Navare H, Wang D, Gong Y, Wessel J, Moss J . CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009; 2(4):362-70. PMC: 2761685. DOI: 10.1161/CIRCGENETICS.109.857839. View

11.

Roden D, Johnson J, Kimmel S, Krauss R, Medina M, Shuldiner A . Cardiovascular pharmacogenomics. Circ Res. 2011; 109(7):807-20. PMC: 3201825. DOI: 10.1161/CIRCRESAHA.110.230995. View

12.

Nolan D, Kraus W, Hauser E, Li Y, Thompson D, Johnson J . Genome-wide linkage analysis of cardiovascular disease biomarkers in a large, multigenerational family. PLoS One. 2013; 8(8):e71779. PMC: 3732259. DOI: 10.1371/journal.pone.0071779. View

13.

Millican E, Lenzini P, E Milligan P, Grosso L, Eby C, Deych E . Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007; 110(5):1511-5. PMC: 1975838. DOI: 10.1182/blood-2007-01-069609. View

14.

Kaminsky L, Zhang Z . Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73(1):67-74. DOI: 10.1016/s0163-7258(96)00140-4. View

15.

Sconce E, Khan T, Wynne H, Avery P, Monkhouse L, King B . The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106(7):2329-33. DOI: 10.1182/blood-2005-03-1108. View

16.

Gulseth M, Grice G, Dager W . Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm. 2009; 66(2):123-33. DOI: 10.2146/ajhp080127. View

17.

Wang X, Cheng S, Brophy V, Erlich H, Mannhalter C, Berger K . A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. Stroke. 2009; 40(3):683-95. PMC: 2757095. DOI: 10.1161/STROKEAHA.108.524587. View

18.

Al-Eitan L, Elsaqa B, Almasri A, Aman H, Khasawneh R, Alghamdi M . Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease. Pharmgenomics Pers Med. 2020; 13:619-632. PMC: 7680183. DOI: 10.2147/PGPM.S274246. View

19.

Tang Q, Zou H, Guo C, Liu Z . Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis. Int J Cardiol. 2014; 175(3):587-91. DOI: 10.1016/j.ijcard.2014.06.031. View

20.

Al-Eitan L, Almasri A, Khasawneh R . Impact of and Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy. Genes (Basel). 2018; 9(12). PMC: 6316567. DOI: 10.3390/genes9120578. View